Estrogens esterified
Amnestrogen, Duavee, Estratab, Evex, Femogen, Menrium, Milprem, Pmb, Premarin, Premphase, Prempro (estrogens, esterified) is an unknown pharmaceutical. Estrogens, esterified was first approved as Menrium 5-2 on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Premarin (generic drugs available since 1982-01-01, discontinued: Amnestrogen, Estratab, Evex, Femogen)
CombinationsDuavee, Premphase, Prempro (discontinued: Menrium, Milprem, Pmb, Premphase (premarin;cycrin ), Prempro (premarin;cycrin))
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bazedoxifene acetate
+
Estrogens
+
conjugated
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUAVEE | WYETH PHARMS | N-022247 RX | 2013-10-03 | 1 products, RLD, RS |
Chlordiazepoxide
+
Estrogens
+
esterified
Estrogens
+
conjugated
Estrogens
+
conjugated
+
Medroxyprogesterone acetate
Estrogens
+
conjugated
+
Meprobamate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MILPREM-400 | Medpointe Pharm Hlc | N-011045 DISCN | 1982-01-01 | 1 products |
| MILPREM-200 | Medpointe Pharm Hlc | N-011045 DISCN | 1982-01-01 | 1 products |
| PMB 400 | Wyeth | N-010971 DISCN | 1982-01-01 | 1 products |
| PMB 200 | Wyeth | N-010971 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA14: Nomegestrol and estradiol
— G03AA17: Medroxyprogesterone and estradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB08: Dienogest and estradiol
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CA: Natural and semisynthetic estrogens, plain
— G03CA03: Estradiol
— G03CA53: Estradiol, combinations
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CC: Anti-gonadotropin-releasing hormones
— H01CC53: Elagolix, estradiol and norethisterone
— H01CC54: Relugolix, estradiol and norethisterone
HCPCS
No data
Clinical
Clinical Trials
147 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 6 | 8 | 4 | 6 | 2 | 26 |
| Hot flashes | D019584 | — | — | — | — | 3 | 2 | 2 | 7 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 3 | 2 | 6 |
| Atrophic vaginitis | D059268 | EFO_1001271 | — | 2 | — | 1 | 2 | 1 | 6 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | 1 | 2 | 1 | — | 4 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 2 | 2 | 4 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 2 | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 1 | — | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | — | 1 | 1 | — | 2 |
| Pelvic floor disorders | D059952 | — | — | — | — | — | 2 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopause | D017698 | — | — | 8 | 4 | 2 | — | 3 | 17 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 8 | 6 | — | 1 | 15 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 2 | — | 2 | 9 |
| Adenocarcinoma | D000230 | — | — | 1 | 6 | 1 | — | — | 8 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 6 | — | 2 | 8 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 4 | — | — | 5 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | 3 | — | — | 4 |
| Coronary disease | D003327 | — | — | — | 1 | 4 | — | — | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | — | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | — | — | 2 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Risk reduction behavior | D040242 | — | — | — | 1 | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
| Prehypertension | D058246 | — | — | — | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | — | — | — | 1 | 2 |
| Estrogen replacement therapy | D015914 | — | — | 2 | — | — | — | — | 2 |
| Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | — | — | — | — | 1 |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 1 | 1 |
| Gender dysphoria | D000068116 | — | F64 | — | — | — | — | 1 | 1 |
| Breast density | D000071060 | — | — | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estrogens esterified |
| INN | — |
| Description | 17beta-estradiol is the 17beta-isomer of estradiol. It has a role as an estrogen, a human metabolite, an EC 1.2.3.1 (aldehyde oxidase) inhibitor, a Daphnia magna metabolite, a mouse metabolite and a geroprotector. It is a 17beta-hydroxy steroid and an estradiol. |
| Classification | Unknown |
| Drug class | estrogens; steroids (androgens, anabolics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 141290-02-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201468 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09381 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Premarin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,932 documents
View more details
Safety
Black-box Warning
Black-box warning for: Duavee, Menest, Premarin, Premphase, Premphase prempro, Prempro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
55,051 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use